Catriona S. Bradshaw

Catriona S. Bradshaw

Auto-generated profile, based on publicly available information

Catriona S. Bradshaw

Melbourne Sexual Health Centre, Alfred Health

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
CBCatriona S. Bradshaw
Catriona S. Bradshaw
AMAnna N. Morton
Anna N. Morton
JHJane Hocking
Jane Hocking
SGSuzanne M. Garland
Suzanne M. Garland
MMMargaret B. Morris
Margaret B. Morris
CFChristopher K. Fairley
Christopher K. Fairley
BackgroundWe wished to determine recurrences of bacterial vaginosis (BV) after treatment over the course of 12 months and to establish factors associ

1 November 2017 in Research in Microbiology
Verified
Journal Article
Open access
Gilda TachedjianGilda Tachedjian
Gilda Tachedjian
MAMuriel Aldunate
Muriel Aldunate
CBCatronia S. Bradshaw
Catronia S. Bradshaw
RCRichard Cone
Richard Cone
Vaginal eubiosis is characterised by beneficial lactobacillus-dominated microbiota. In contrast, vaginal dysbiosis (e.g. bacterial vaginosis, BV), characterised by an overgrowth of multiple anaerobes, is associated with an increased risk of adverse urogenital and reproductive health outcomes. A major distinguishing feature between the vaginal environment in states of eubiosis and dysbiosis is a high concentration of lactic acid, produced by lactobacilli, that acidifies the vagina in eubiosis versus a sharp drop in lactic acid and an increase in pH in dysbiosis. Here we review the antimicrobial, antiviral and immunomodulatory properties of lactic acid and the use of lactic acid and lactobacilli probiotics in preventing or treating BV.

15 December 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JJJørgen Skov Jensen
Jørgen Skov Jensen
CBCatriona S. Bradshaw
Catriona S. Bradshaw
STSepehr N. Tabrizi
Sepehr N. Tabrizi
CFChristopher K. Fairley
Christopher K. Fairley
RHRyoichi Hamasuna
Ryoichi Hamasuna
Background.Mycoplasma genitalium is a common cause of nongonococcal urethritis. Treatment trials have shown that doxycycline is inefficient, whereas

1 December 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KFKatherine A. Fethers
Katherine A. Fethers
CFChristopher K. Fairley
Christopher K. Fairley
JHJane S. Hocking
Jane S. Hocking
LGLyle C. Gurrin
Lyle C. Gurrin
CBCatriona S. Bradshaw
Catriona S. Bradshaw
We performed a systematic review and meta-analysis of the association between sexual risk factors and bacterial vaginosis (BV). Forty-three studies r

19 July 2016 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
CBCatriona S. Bradshaw
Catriona S. Bradshaw
JSJack D. Sobel
Jack D. Sobel
Practitioners and patients alike widely recognize the limitations of current therapeutic approaches to the treatment of bacterial vaginosis (BV). Options remain extremely limited, and our inability to prevent the frequently, often relentless symptomatic recurrences of BV and to reduce serious sequelae such as preterm delivery, remains an acknowledged but unresolved shortcoming. Our incomplete understanding of the pathophysiology of this unique form of vaginal dysbiosis has been a significant impediment to developing optimal treatment and prevention approaches. New drugs have not been forthcoming and are not likely to be available in the immediate future; hence, reliance on the optimal use of available agents has become essential as improvised often unproven regimens are implemented. In this review, we will explore the limitations of currently recommended therapies, with a particular focus on the contribution of reinfection and pathogen persistence to BV recurrence, and the development of interventions that target these mechanisms. Ultimately, to achieve sustained cure and effectiveness against BV-associated sequelae, it is possible that we will need approaches that combine antimicrobials with biofilm-disrupting agents and partner treatments in those at risk of reinfection.

1 February 2006 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
CBCatriona S. Bradshaw
Catriona S. Bradshaw
STSepehr N. Tabrizi
Sepehr N. Tabrizi
TRTimothy R. H. Read
Timothy R. H. Read
SGSuzanne M. Garland
Suzanne M. Garland
CHCarol A. Hopkins
Carol A. Hopkins
CFChristopher K. Fairley
Christopher K. Fairley
BackgroundThe purpose of the present study was to determine pathogens and behaviors associated with nongonococcal urethritis (NGU) and the usefulness of the urethral smear in predicting the presence of pathogens